Direct oral anticoagulants (DOACs), previously also known as novel oral anticoagulants
(NOACs), have increased the therapeutic options for stroke prevention in atrial fibrillation …

Background Recently published studies indicated a high proportion of patients taking direct
oral anticoagulants (DOACs) are off-label under-or overdosed. The present study aimed at …

Abstract In 2012, the Dutch Health Council published a report addressing barriers for an
early and broad introduction of direct oral anticoagulants (DOACs). The report raised …

Introduction Direct oral anticoagulants (DOAC) are increasingly used for the prevention and
treatment of thromboembolic events. However, only little evidence is available regarding the …

Since their market approval, direct oral anticoagulants (DOACs) are being increasingly used
for stroke prevention in patients with atrial fibrillation. However, the management of DOAC …

DOACs begin working faster than warfarin. They also leave the body faster than warfarin.
For example, a DOAC thins the blood and gives full blood clot protection within a few hours …

New guideline recommendations prefer direct oral anticoagulants (DOACs) over warfarin in
DOAC-eligible patients with atrial fibrillation and patients with venous thromboembolism. As …

Oral anticoagulant therapy (OAT) is widely used to prevent and treat thromboembolic events.
Traditionally, warfarin has been the drug of choice and, indeed, this drug is effective and …

Oral anticoagulants (OACs) are high alert medications and require high-quality
management to optimize health outcomes. The objective of this scoping review was to …

Background Various anticoagulant therapies are prescribed to patients under physicians'
discretion and recently Direct Oral Anticoagulants (DOAC) have been under trials to …